Literature DB >> 20594300

Severe leukocytoclastic vasculitis secondary to the use of a naproxen and requiring amputation: a case report.

Keri Brown1, Jeanine Martin, Susan Zito.   

Abstract

INTRODUCTION: Leukocytoclastic vasculitis (also known as hypersensitivity vasculitis and cutaneous necrotizing vasculitis) can present with various manifestations, which often delays the diagnosis and treatment. In order to show the importance of the early recognition of leukocytoclastic vasculitis, we present a case which occurred secondary to the use of a common pharmaceutical, naproxen. We were unable to find a case of leukocytoclastic vasculitis secondary to naproxen in the literature. CASE
PRESENTATION: We present the case of a 33-year-old African American woman with below the knee and bilateral digital gangrene from hypersensitivity vasculitis secondary to the non-steroidal anti-inflammatory medication naproxen.
CONCLUSION: This is an original case report focusing on the rheumatologic management of leukocytoclastic vasculitis. However, other specialties, such as internal medicine, dermatology, infectious disease, general surgery and pathology, can gain valuable information by reviewing this case report. Reporting a case of leukocytoclastic vasculitis secondary to treatment with naproxen will advance our understanding of this disease etiology by adding yet another non-steroidal anti-inflammatory drug to the list of potential causes of leukocytoclastic vasculitis.

Entities:  

Year:  2010        PMID: 20594300      PMCID: PMC2906497          DOI: 10.1186/1752-1947-4-204

Source DB:  PubMed          Journal:  J Med Case Rep        ISSN: 1752-1947


  14 in total

Review 1.  Dapsone: unapproved uses or indications.

Authors:  R Wolf; B Tüzün; Y Tüzün
Journal:  Clin Dermatol       Date:  2000 Jan-Feb       Impact factor: 3.541

2.  The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis.

Authors:  L H Calabrese; B A Michel; D A Bloch; W P Arend; S M Edworthy; A S Fauci; J F Fries; G G Hunder; R Y Leavitt; J T Lie
Journal:  Arthritis Rheum       Date:  1990-08

3.  Leukocytoclastic vasculitis--correlation between different histologic stages and direct immunofluorescence results.

Authors:  M H Grunwald; I Avinoach; B Amichai; S Halevy
Journal:  Int J Dermatol       Date:  1997-05       Impact factor: 2.736

Review 4.  Possible pathogenetic mechanisms in allergic cutaneous vasculitis.

Authors:  N Tosca; J D Stratigos
Journal:  Int J Dermatol       Date:  1988-06       Impact factor: 2.736

5.  Clinical features and outcome of 95 patients with hypersensitivity vasculitis.

Authors:  V M Martinez-Taboada; R Blanco; M Garcia-Fuentes; V Rodriguez-Valverde
Journal:  Am J Med       Date:  1997-02       Impact factor: 4.965

6.  Drug associated cutaneous vasculitis in adults in northwestern Spain.

Authors:  C García-Porrúa; M A González-Gay; L López-Lázaro
Journal:  J Rheumatol       Date:  1999-09       Impact factor: 4.666

Review 7.  Colchicine in dermatology.

Authors:  T P Sullivan; L E King; A S Boyd
Journal:  J Am Acad Dermatol       Date:  1998-12       Impact factor: 11.527

8.  Necrotizing fasciitis. Case report.

Authors:  Mario Costanzo; Laura Antonella Maria Caruso; Francesca Condorelli; Vincenzo Cassaro; Francesco Longo; Giuseppe Forzisi; Matteo Angelo Cannizzaro
Journal:  Ann Ital Chir       Date:  2008 Jul-Aug       Impact factor: 0.766

9.  Staging of necrotizing fasciitis based on the evolving cutaneous features.

Authors:  Yi-Shi Wang; Chin-Ho Wong; Yong-Kwang Tay
Journal:  Int J Dermatol       Date:  2007-10       Impact factor: 2.736

10.  Idiopathic hypersensitivity vasculitis: clinicopathologic correlation of 61 cases.

Authors:  K V Ratnam; Y H Boon; B K Pang
Journal:  Int J Dermatol       Date:  1995-11       Impact factor: 2.736

View more
  2 in total

1.  Dermatologic Diagnosis: Leukocytoclastic Vasculitis.

Authors:  Joseph Einhorn; Joel T Levis
Journal:  Perm J       Date:  2015

2.  A not-so-sweet diagnosis - leukocytoclastic vasculitis masquerading as squamous cell carcinoma.

Authors:  Mussa Mensa; Zita M Jessop; Nick Wilson-Jones; Iain S Whitaker
Journal:  Int Wound J       Date:  2016-09-29       Impact factor: 3.315

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.